Suzhou Dading Pharmaceutical Technology

Suzhou Dading Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Suzhou, China, focused on the development of innovative small molecule drugs. The company targets high-unmet-need therapeutic areas, specifically central nervous system (CNS) disorders and oncology. Founded by Dr. Jianqi Li, a renowned medicinal chemist from the Shanghai Institute of Pharmaceutical Industry, the company leverages a proprietary R&D platform to advance its pipeline of Class 1 innovative candidates. Its lead program, DD-101, is a multi-target kinase inhibitor currently in clinical development for the treatment of solid tumors. Additionally, the company is developing novel dual-action inhibitors for neurodegenerative conditions such as Alzheimer's and Parkinson's diseases.